Kratom Toxicity: Pharmacologic Mechanisms, Clinical Risks, and Management Considerations

Kratom (Mitragyna speciosa) is an opioid-like botanical increasingly used for self-management of pain and opioid withdrawal and has been increasingly implicated in emergency department presentations for acute toxicity. Despite its growing use, kratom remains poorly understood in clinical practice, particularly with respect to its complex, metabolite-dependent pharmacology. Product heterogeneity, variable alkaloid composition, and frequent polysubstance use further complicate clinical recognition and management, raising important patient safety concerns. This narrative review synthesizes the published clinical, toxicological, and pharmacologic literature on kratom toxicity, including case reports, case series, observational studies, and prior reviews, with particular emphasis on respiratory depression, naloxone responsiveness, and post-reversal management considerations. Available evidence suggests that kratom-associated toxicity can produce opioid-like toxidromes with variable responsiveness to naloxone. Reported cases demonstrate heterogeneity in clinical presentation and reversal, likely reflecting differences in alkaloid composition, metabolite activity, product variability, and co-ingestant exposure. Published reports also describe delayed or recurrent respiratory depression following initial naloxone response, creating challenges regarding appropriate observation periods and disposition decisions. These risks may be further amplified by polysubstance use and variability among commercially available kratom preparations. Kratom-associated toxicity represents an evolving patient safety challenge in acute care settings. Clinicians should recognize the potential for delayed or recurrent respiratory depression following naloxone administration and consider extended observation in selected patients to reduce preventable morbidity.